WO1999011256A1 - L-threonate ferreux, composition pharmaceutique le contenant et son utilisation pour reduire et traiter l'anemie chez l'homme - Google Patents
L-threonate ferreux, composition pharmaceutique le contenant et son utilisation pour reduire et traiter l'anemie chez l'homme Download PDFInfo
- Publication number
- WO1999011256A1 WO1999011256A1 PCT/CN1998/000174 CN9800174W WO9911256A1 WO 1999011256 A1 WO1999011256 A1 WO 1999011256A1 CN 9800174 W CN9800174 W CN 9800174W WO 9911256 A1 WO9911256 A1 WO 9911256A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anemia
- threonate
- ferrous
- iron
- group
- Prior art date
Links
- JPIJQSOTBSSVTP-STHAYSLISA-N L-threonic acid Chemical compound OC[C@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-STHAYSLISA-N 0.000 title claims abstract description 92
- 208000007502 anemia Diseases 0.000 title claims abstract description 59
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 160
- 229910052742 iron Inorganic materials 0.000 claims abstract description 77
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- 208000036581 Haemorrhagic anaemia Diseases 0.000 claims description 20
- 208000007475 hemolytic anemia Diseases 0.000 claims description 20
- 229940056902 l- threonic acid Drugs 0.000 claims description 16
- 208000036654 deficiency anemia Diseases 0.000 claims description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- 229940022036 threonate Drugs 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 6
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910001853 inorganic hydroxide Inorganic materials 0.000 claims description 2
- 229910052809 inorganic oxide Inorganic materials 0.000 claims description 2
- 238000005649 metathesis reaction Methods 0.000 claims description 2
- IMYZCYXTVFOXAQ-LJUKVTEVSA-N calcium;(2r,3s)-2,3,4-trihydroxybutanoic acid Chemical compound [Ca].OC[C@H](O)[C@@H](O)C(O)=O IMYZCYXTVFOXAQ-LJUKVTEVSA-N 0.000 claims 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 35
- 239000008280 blood Substances 0.000 abstract description 35
- 230000002949 hemolytic effect Effects 0.000 abstract description 5
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 41
- 241001465754 Metazoa Species 0.000 description 35
- 229940079593 drug Drugs 0.000 description 31
- 108010054147 Hemoglobins Proteins 0.000 description 26
- 102000001554 Hemoglobins Human genes 0.000 description 26
- 210000003743 erythrocyte Anatomy 0.000 description 25
- 239000002689 soil Substances 0.000 description 21
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 102000008857 Ferritin Human genes 0.000 description 14
- 108050000784 Ferritin Proteins 0.000 description 14
- 238000008416 Ferritin Methods 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 12
- 210000001995 reticulocyte Anatomy 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 239000011790 ferrous sulphate Substances 0.000 description 11
- 235000003891 ferrous sulphate Nutrition 0.000 description 11
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 230000029087 digestion Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 238000004820 blood count Methods 0.000 description 8
- 230000009469 supplementation Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000004222 ferrous gluconate Substances 0.000 description 7
- 229960001645 ferrous gluconate Drugs 0.000 description 7
- 235000013924 ferrous gluconate Nutrition 0.000 description 7
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 6
- -1 salt derivatives of L-threonic acid Chemical class 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000032023 Signs and Symptoms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- ZJXGOFZGZFVRHK-BALCVSAKSA-L calcium;(2r,3s)-2,3,4-trihydroxybutanoate Chemical compound [Ca+2].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O ZJXGOFZGZFVRHK-BALCVSAKSA-L 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 239000011773 ferrous fumarate Substances 0.000 description 3
- 229960000225 ferrous fumarate Drugs 0.000 description 3
- 235000002332 ferrous fumarate Nutrition 0.000 description 3
- 244000144993 groups of animals Species 0.000 description 3
- 229910021506 iron(II) hydroxide Inorganic materials 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000010953 Ames test Methods 0.000 description 2
- 231100000039 Ames test Toxicity 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 239000005569 Iron sulphate Substances 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 231100000005 chromosome aberration Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000014413 iron hydroxide Nutrition 0.000 description 2
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 206010054877 Mucosal discolouration Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 231100000238 embryotoxicity Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940082629 iron antianemic preparations Drugs 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- UICBCXONCUFSOI-UHFFFAOYSA-N n'-phenylacetohydrazide Chemical compound CC(=O)NNC1=CC=CC=C1 UICBCXONCUFSOI-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000012307 pale mucous membrane Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960000468 sulfalene Drugs 0.000 description 1
- KXRZBTAEDBELFD-UHFFFAOYSA-N sulfamethopyrazine Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 KXRZBTAEDBELFD-UHFFFAOYSA-N 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/10—Polyhydroxy carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
Definitions
- the present invention relates to new L-threonic acid derivatives which can be used as medicines, and in particular, it relates to L-threonic acid, a method for preparing the same and a pharmaceutical composition thereof, and L-threonic acid.
- L-threonic acid is one of the main degradation products of vitamin C. Some functional effects of vitamin C are actually realized by its degradation products such as L-threonic acid. In turn, the existence of these degradation products is Influence on the biological function or metabolic mechanism of vitamin C.
- L-threonate is a derivative of L-threonate.
- it can also be used as a highly effective molecular calcium nutrition fortifier to prevent and treat various It is a disease caused by calcium deficiency; at the same time, it has been found that calcium L-threonate has obvious effects in anti-inflammatory and analgesic and lowering blood pressure.
- other metal salt derivatives of L-threonic acid and their use as drugs and to treat diseases have not been reported.
- Anemia is a common disease. There are many reasons for anemia, which are mainly: (1) a decrease in the volume or number of red blood cells in the blood; (2) a decrease in hemoglobin, such as chronic or acute blood loss or destruction of red blood cells due to exposure to hemolytic chemicals; (3) ) Reduced red blood cells produced, for example, anemia caused by a lack of bone marrow or nutrients such as B 12 and iron.
- Iron deficiency anemia also known as nutritional anemia, is the most common type of anemia, which is caused by an increase in iron loss in the body and reduces iron storage, such as caused by growth, pregnancy, or other chronic blood loss. Body iron loss or lack of body iron due to insufficient daily intake of iron, etc.
- Iron deficiency anemia is a worldwide nutrition problem. After suffering from IDA, even fortified foods with high iron content cannot replace the drug iron for treatment.
- ferrous sulfate is the first choice because of its high efficacy, low price, and abundant drug sources, but its high side effects make the treatment of IDA by oral iron very limited, see China Pediatric Blood No. 1, 1996, pp. 24-26. Therefore, there is a need to provide an effective method for improving and treating iron deficiency anemia. Compounds and pharmaceutical compositions thereof.
- hemorrhagic anemia refers to anemia caused by blood loss in the body, such as a woman's menstrual period or pregnancy.
- hemolytic anemia Another type of anemia is hemolytic anemia.
- the cause of hemolytic anemia is mainly due to the body's exposure to hemolytic chemicals such as sulfa and naphthalene, or the production of antibodies to cells due to medication, or the presence of genetically defective cells in the body.
- the main method for treating hemolytic anemia is to remove the above-mentioned hemolytic substances and the like from the body. Therefore, there is a need to provide a compound for improving and treating hemolytic anemia and a pharmaceutical composition thereof. In particular, there is a need for a compound capable of simultaneously improving and treating nutritional anemia, hemorrhagic anemia, and hemolytic anemia, and a pharmaceutical composition thereof.
- the object of the present invention is to provide a novel L-threonic acid derivative, especially L-threonic acid.
- Another object of the present invention is to provide a pharmaceutical composition for improving and treating anemia such as iron deficiency anemia, hemorrhagic anemia, and hemolytic anemia.
- a further object is to provide a method for improving and treating such anemia.
- the ferrous L-threonate of the present invention has a highly efficient absorption characteristic.
- the state of the animal body is the same as the iron intake, the ratio of L-threonate digestion and absorption is higher.
- Ferrous sulfate has high digestion and absorption, and is safe and non-toxic.
- the ferrous L-threonate as an iron preparation has high absorption characteristics and slow-release function, and has obvious pharmacological effects on improving and treating diseases such as hemolytic anemia, hemorrhagic anemia, iron deficiency anemia, and hemoglobin, and is obviously superior to Ferrous gluconate and ferrous fumarate can be used as medicines and iron supplements to improve and treat anemia.
- the present invention provides ferrous L-threonate and its hydrate having the following formula (I):
- the ferrous L-threonate of the present invention has a left-handed optically active structure, is easily soluble in water, and is in solution.
- the preparation method of the ferrous L-threonate according to the present invention is:
- L-threonic acid or an inorganic salt of calcium L-threonate and divalent iron such as ferrous sulfate, ferrous chloride, and ferrous nitrate, wherein L-threonic acid can be obtained as vitamin C It can also be obtained from raw materials. Calcium L-threonate can also be obtained by directly replacing the calcium with weak acid.
- the above-mentioned inorganic salt, oxide or hydroxide of divalent iron may be composed of an inorganic salt of trivalent iron such as iron nitrate, triferric acid, iron oxide or hydroxide such as iron hydroxide or other substances such as Obtained from ferric tetroxide.
- a method for preparing ferrous L-threonate according to the present invention comprising:
- L-threonic acid may be reacted with ferrous oxide, hydroxide or salt to form ferrous L-threonic acid.
- the present invention also relates to a pharmaceutical composition comprising ferrous L-threonate as an active ingredient.
- the composition of ferrous L-threonate of the present invention may include other active substances and any pharmaceutically acceptable carrier, and pharmaceutical excipients such as flavoring agents, excipients, vitamins and other pharmaceutical additives.
- L - threonate compositions comprising ferrous L - threonate ferrous, vitamin C or ⁇ 12, wherein L - ferrous threonate is about 10% of the composition by weight - A 90% It is preferably about 30-80%, more preferably 40-60% such as 50%.
- “Pharmaceutically acceptable” means those whose properties and / or substances are acceptable to the patient from a pharmacological point of view, and that the composition, formulation, stability, bioavailability is acceptable to the pharmacist who makes the drug of.
- the ferrous L-threonate of the present invention can be made into any pharmaceutical dosage form.
- suitable dosage forms include, for example, tablets, capsules, suppositories, solutions, suspensions, syrups, emulsions, gels, ointments, lyophilized powders, pills, films, liposomes, dispersible powders or Solution for injection.
- Solid dosage forms such as tablets are preferred.
- the active substance L-ferrous threonate can be combined with known excipients such as inert diluents such as calcium carbonate, calcium phosphate and lactose, disintegrating agents such as corn starch, binders such as starch or gelatin, Lubricants such as magnesium stearate or talc, and substances which can produce a sustained-release effect such as carboxypolymethylene, carboxymethyl cellulose and the like are mixed to prepare tablets.
- excipients such as inert diluents such as calcium carbonate, calcium phosphate and lactose, disintegrating agents such as corn starch, binders such as starch or gelatin, Lubricants such as magnesium stearate or talc, and substances which can produce a sustained-release effect such as carboxypolymethylene, carboxymethyl cellulose and the like are mixed to prepare tablets.
- Sugar-coated tablets can be produced in a similar manner by coating cores made in the same manner as described above with substances commonly used for sugar-coated tablets such as shellac, Arabic, talc, titanium dioxide and sugar. To avoid incompatibilities, the core may also include multiple layers.
- Solutions for injection can be produced in a general manner, for example, by adding a preservative such as a paraben or a stabilizer such as an alkali metal salt of ethylenediaminetetraacetic acid, and then transferring it to an injection bottle.
- a preservative such as a paraben or a stabilizer such as an alkali metal salt of ethylenediaminetetraacetic acid
- compositions such as suppositories and the like can be prepared by methods known in the art.
- ferrous L-threonate can also be used in the form of food additives, beverage additives, and flavor additives, such as being added to bread, eating through daily diet, and achieving the purpose of iron supplementation to improve and treat anemia.
- anemia such as nutritional anemia, hemorrhagic anemia, and hemolytic anemia using L-threonate.
- a method for improving and treating anemia according to the present invention includes administering a certain amount of ferrous L-threonate to the subject.
- the method for improving and treating anemia of the present invention can be applied to animals, such as mammals such as cattle, horses, and sheep, and is particularly suitable for improving and treating anemia in humans, such as children, women, or the elderly. This is especially true for people with a high incidence of anemia, such as children and women.
- Ferrous (I) threonate can be active by oral, parenteral administration such as injection or topical route.
- the required therapeutic dose depends on the condition and the mode of administration used.
- the precise amount to be administered may also vary depending on the specific circumstances, such as the degree of anemia, the age and weight of the patient, for example, for children, the dosage should be reduced as appropriate.
- the amount of ferrous L-threonate is generally 10mg-lg / day / adult, preferably 20mg-800mg / day / adult, preferably 30-500 mg / day / adult such as 30mg 250 mg or 400 mg, more preferably 50-200 mg / day / adult such as 60 mg, 100 mg, 150 mg.
- the method for treating anemia of animals, especially mammals other than humans, according to the present invention The amount of ferrous L-threonate can be determined experimentally depending on the animal.
- the method for improving the treatment of anemia of the present invention can treat iron deficiency anemia and hemorrhagic anemia, such as body iron loss caused by growing period, pregnancy, menstruation or other chronic blood loss, or body iron caused by insufficient daily intake of iron. Anemia due to deficiency.
- the method for treating anemia of the present invention can treat hemolytic anemia, such as anemia caused by reduction of hemoglobin due to destruction of red blood cells due to exposure to hemolytic chemicals.
- the invention also relates to the use of ferrous L-threonate as an adjuvant in the treatment of diseases such as systemic dysfunction caused by iron deficiency.
- the toxicity of ferrous L-threonate was evaluated using the method of GB15193.4-94 Horne's method.
- the LD50 of the rats is: 3.16g / kg for females and 3.69g for males. This indicates that L-threonate is practically non-toxic.
- the Ames test was performed, indicating that L-threonic acid
- the results of ferrous iron by Ames test, bone marrow micronucleus test, and mouse testicular chromosome aberration test were all negative. No rat fetal L-threonate had embryo toxicity and teratogenic effects.
- male rats are used to study the digestion and absorption of ferrous L-threonate. For details, see Experiment 1.
- the present invention has also studied the efficacy of L-threonate on hemolytic anemia rats, nutritional anemia rats, and hemorrhagic anemia rats. For details, see Experiment 2.
- the present invention has also conducted clinical studies on the improvement of nutritional anemia by L-threonate. For details, see Experiment 3. Experiment 1. Study on the digestion and absorption of L-threonate
- ferrous L-threonate provided by Beijing Juneng Life Science Research Center was used.
- the molecular formula is Fe (C 4 H 7 0 5 ) 2 ⁇ 2 ⁇ 2 0, molecular weight: 362, iron-containing 15. 47%, Soluble in water, yellow-green powder, no odor.
- the experimental animals used healthy male Wistra rats provided by the Experimental Animal Center of Heilongjiang Cancer Institute, weighing 140-180g.
- Iron sulphate (positive control) group Fe, 2.5 mg / kg, iron sulphate 12.43 mg / kg; negative control (low iron feed) group: Fe, Q. 9 mg / kg (in the measured feed) Iron content)
- the 3 day feces were collected, dried at 80-90 ° C, weighed, and pulverized over 40-60 mesh, 0.5-0.6 g was taken, and digested with 4: 1 nitric acid: perchloric acid. To the end, the volume was set at 10 ml, and the iron content was measured by atomic absorption method. Then calculate the average iron digestion and absorption rate (%) of each animal and each group of animals according to the following formula:
- Negative control (low iron feed) 1 0 0. 9 55. 50 ⁇ 1. 85 group
- Drug L-ferrous threonate is the same as experiment one; Active ingredients of ferrous gluconate: 11% iron content, yellow-green powder, easily soluble in water, sealed and stored at normal temperature, provided by Jiangxi Ganjiang Pharmaceutical Co., Ltd .; rich Iron content of ferrous maleate is 6.4%, provided by Shanghai No. 18 Pharmaceutical Factory. The above drugs were diluted with distilled water at the experimentally administered dose.
- Wi s tar rats male, weighing 250 to 10 g, were provided by the Animal Center of Beijing Medical University. Animals ate a normal water diet, and feed was purchased from the Animal Center of Beijing Medical University.
- Acetylphenylhydrazine (CJi! 0). Acetylhydrazine was purchased from Beijing Biochemical Reagent Company and produced by Beijing Fuxing Chemical Plant. Dosage: Prior to the experiment, each rat was subcutaneously injected with a 4% acetophenazine physiological saline solution 57 g / g, and the hemoglobin content in the blood was checked on the 2nd and 4th days after the injection, until the peripheral hemoglobin decreased to 6. 11 0.25. At %%, anemia model animals were divided into high-dose group, medium-dose group, low-dose group, known drug control group, model animal control group, and normal animal control group, with 18 rats in each group.
- Hemoglobin was measured every 7 days in 8 groups of animals. After 4 weeks of feeding, the hemoglobin of the iron-deficiency anemia group decreased to 7.51 ⁇ 0.17g, and one group of model animals and one group of normal control animals were taken from each group. Ten blood samples were taken for experimental observation index determination, and served as a control for animal observation indexes before taking the medicine. The remaining 5 groups of iron-deficiency model animals and 1 group of normal controls were treated with L-threonate to treat iron-deficiency anemia in rats. The two model animals were kept in an animal breeding room with an indoor temperature of 23 ° C, an average humidity of 60%, and a light time of 10 hours.
- the remaining 6 groups of animals were randomly divided according to the experimental design into a high-dose L-threonate group, a medium-dose group, a low-dose group, a known drug, ferrous gluconate group, ferrous fumarate group, and model control group.
- Group of 15 rats Five rats were sacrificed in each experimental group 12 days after the administration, and 10 rats were sacrificed in each group 18 days after the administration, and various indexes were measured. Changes in hemoglobin content were monitored every 6 days during the experiment.
- the actual amount of ferrous iron taken by the rats in each group was: 17.28 mg Fe / kg in the high-dose group; 8.61 ⁇ 2 g Fe / kg in the medium-dose group; 4, 32 mg Fe / kg in the low-dose group; 8.64 mg Fe / kg in the positive drug group.
- the animals in each group of iron-deficiency anemia continued to take low-iron feed and deionized water feed while taking the medicine, and the normal animal control group used normal feed and tap water feed.
- the hemolytic anemia rats were taken for 2 weeks, and the changes of whole blood iron content and serum ferritin content were observed, as shown in Table 5.
- Rat hemoglobin (Hb) depletion test (making of a rat model of iron deficiency anemia)
- the test was performed for 28 days.
- the changes of hemoglobin in each group are shown in Table 6-7.
- n 10 groups RBC (X10 12 / L) reticulocyte whole blood iron content serum ferritin
- L-threonate medium dose group 7. 40 ⁇ 0. 54 8. 35 ⁇ 0. 21 10. 67 ⁇ 0. 37 12. 14 + 0. 27
- L-threonate low-dose group 7.61 + 0. 53 8. 00 ⁇ 0. 42 10. 20 ⁇ 0. 49 11. 26 ⁇ 0. 79 ferrous gluconate group 7, 50 + 0. 76 7. 95 ⁇ 0. 30 1 0. 50 ⁇ 0. 61 11. 80 ⁇ 0. 63 Ferrous fumarate group 1, .43 ⁇ 0. 85 7. 80 ⁇ 0. 24 10. 12 + 0. 52 11. 84 ⁇ 0. 45 Model control group 7. 51 ⁇ 0. 63 7. 42 ⁇ 0. 26 9. 03 ⁇ 0. 56 10. 39 ⁇ 0.
- Test methods For children with nutritional anemia before and after the experiment, 10 ⁇ 1 of ear blood was collected, 5 ml of arm veins (3 ml non-anticoagulant, 2 ml anticoagulant), and the following indicators were measured.
- Hb The cyanide methemoglobin method was used. Take 10 ⁇ 1 ear blood, add -Add 5ml of acidified diluent, mix well, and measure with SH hemoglobin meter.
- the ferritinated hemoglobin standard is provided by Shanghai Medical Laboratory, and the SH hemoglobin meter is produced by Jiangsu Huguang Instrument Factory.
- FEP free protoporphyrin
- PCV is hematocrit
- SF kit was provided by Tianjin Jiuding Biological Engineering Co., Ltd. Centrifuge 2ml whole blood, take the supernatant, add samples according to the procedure required by the kit, and measure with SN-682 radioimmuno ⁇ counter.
- the instrument is produced by the Rihuan Instrument Factory of the Shanghai Institute of Medical Nuclear Research, Chinese Academy of Sciences.
- Hb reached normal standard (Hb> 120g / L), increased by 10g / L, other biochemical indicators improved.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/486,569 US6313170B1 (en) | 1997-08-29 | 1998-08-28 | L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof |
DE69832722T DE69832722T2 (de) | 1997-08-29 | 1998-08-28 | Eisen-l-threonat-,pharmazeutische zusammensetzungen und deren verwendung zur verbesserung und behandlung von anämie bei menschen |
KR1020007002104A KR100615537B1 (ko) | 1997-08-29 | 1998-08-28 | 제 1철 l-트레오네이트, 그 약학 조성물 및 인간의 빈혈을 개선 및 치료하기 위해 이를 사용하는 방법 |
AU88512/98A AU8851298A (en) | 1997-08-29 | 1998-08-28 | L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof |
JP2000508359A JP2001514219A (ja) | 1997-08-29 | 1998-08-28 | L−トレオン酸第1鉄、その医療組成物及び人間の貧血疾患を改善及び治療するためのその使用 |
EP98940049A EP1038524B1 (en) | 1997-08-29 | 1998-08-28 | L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof |
HK01102229A HK1032534A1 (en) | 1997-08-29 | 2001-03-27 | L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97116835A CN1053653C (zh) | 1997-08-29 | 1997-08-29 | 新l-苏糖酸衍生物 |
CN97116835.0 | 1997-08-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999011256A1 true WO1999011256A1 (fr) | 1999-03-11 |
WO1999011256A8 WO1999011256A8 (fr) | 1999-08-05 |
Family
ID=5174140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN1998/000174 WO1999011256A1 (fr) | 1997-08-29 | 1998-08-28 | L-threonate ferreux, composition pharmaceutique le contenant et son utilisation pour reduire et traiter l'anemie chez l'homme |
Country Status (9)
Country | Link |
---|---|
US (1) | US6313170B1 (zh) |
EP (1) | EP1038524B1 (zh) |
JP (1) | JP2001514219A (zh) |
KR (1) | KR100615537B1 (zh) |
CN (1) | CN1053653C (zh) |
AU (1) | AU8851298A (zh) |
DE (1) | DE69832722T2 (zh) |
HK (1) | HK1032534A1 (zh) |
WO (1) | WO1999011256A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713513B2 (en) * | 2001-07-03 | 2004-03-30 | Juneng Industry Co., Ltd. | Method for treating cartilage related diseases |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1074762C (zh) * | 1998-08-18 | 2001-11-14 | 北京巨能亚太生命科学研究中心 | L-苏糖酸铬盐、其制备方法及其应用 |
CN1196480C (zh) * | 2001-07-03 | 2005-04-13 | 北京巨能亚太生命科学研究中心 | L-苏糖酸钙在制备预防或治疗骨折的药物中的用途 |
JP4300753B2 (ja) * | 2001-05-31 | 2009-07-22 | 味の素株式会社 | 貧血抑制剤及び食欲抑制剤 |
EP2139466B1 (en) * | 2007-03-22 | 2019-10-23 | Neurocentria, Inc. | Magnesium compositions and uses thereof |
US20080249178A1 (en) | 2007-03-22 | 2008-10-09 | Guosong Liu | Magnesium compositions and uses thereof for increasing lifespan |
US8377473B2 (en) | 2009-07-01 | 2013-02-19 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
CN104961636B (zh) * | 2015-07-14 | 2016-08-31 | 启东东岳药业有限公司 | L-苏糖酸镁合成方法 |
EP3347003A4 (en) | 2015-09-11 | 2019-04-03 | Neurocentria, Inc. | THREATENER BINDINGS AND METHOD FOR USE THEREOF |
CN105326855A (zh) * | 2015-10-27 | 2016-02-17 | 南京大学 | 易吸收复合夹层式螯合镁钙片 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03291231A (ja) * | 1990-04-06 | 1991-12-20 | Asahi Breweries Ltd | 貧血改善剤 |
CN1060216A (zh) * | 1990-09-25 | 1992-04-15 | 奥克斯可尔公司 | 含有治疗活性化合物的组合物及其施用方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4611067A (en) * | 1985-01-31 | 1986-09-09 | Merck & Co., Inc. | Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein |
US4582914A (en) * | 1985-01-31 | 1986-04-15 | Merck & Co., Inc. | Process for the preparation of HMG-CoA reductase inhibitors |
US5070085A (en) * | 1987-04-10 | 1991-12-03 | Oxycal Laboratories, Inc. | Compositions and methods for administering therapeutically active compounds |
WO1990012571A1 (en) * | 1989-04-07 | 1990-11-01 | Oxycal Laboratories, Inc. | Compositions and methods for administering vitamin c |
JPH0678247B2 (ja) * | 1988-10-04 | 1994-10-05 | 大塚製薬株式会社 | Nmr造影用鉄含有製剤 |
CN1228409A (zh) * | 1998-03-05 | 1999-09-15 | 江西赣江制药有限责任公司 | L-苏糖酸和苏糖酸盐(或酯)的制剂 |
-
1997
- 1997-08-29 CN CN97116835A patent/CN1053653C/zh not_active Expired - Fee Related
-
1998
- 1998-08-28 WO PCT/CN1998/000174 patent/WO1999011256A1/zh active IP Right Grant
- 1998-08-28 US US09/486,569 patent/US6313170B1/en not_active Expired - Lifetime
- 1998-08-28 AU AU88512/98A patent/AU8851298A/en not_active Abandoned
- 1998-08-28 JP JP2000508359A patent/JP2001514219A/ja active Pending
- 1998-08-28 KR KR1020007002104A patent/KR100615537B1/ko not_active IP Right Cessation
- 1998-08-28 EP EP98940049A patent/EP1038524B1/en not_active Expired - Lifetime
- 1998-08-28 DE DE69832722T patent/DE69832722T2/de not_active Expired - Fee Related
-
2001
- 2001-03-27 HK HK01102229A patent/HK1032534A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03291231A (ja) * | 1990-04-06 | 1991-12-20 | Asahi Breweries Ltd | 貧血改善剤 |
CN1060216A (zh) * | 1990-09-25 | 1992-04-15 | 奥克斯可尔公司 | 含有治疗活性化合物的组合物及其施用方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1038524A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713513B2 (en) * | 2001-07-03 | 2004-03-30 | Juneng Industry Co., Ltd. | Method for treating cartilage related diseases |
Also Published As
Publication number | Publication date |
---|---|
DE69832722D1 (de) | 2006-01-12 |
KR100615537B1 (ko) | 2006-08-25 |
CN1053653C (zh) | 2000-06-21 |
EP1038524A4 (en) | 2002-08-07 |
KR20010023461A (ko) | 2001-03-26 |
HK1032534A1 (en) | 2001-07-27 |
EP1038524B1 (en) | 2005-12-07 |
JP2001514219A (ja) | 2001-09-11 |
EP1038524A1 (en) | 2000-09-27 |
AU8851298A (en) | 1999-03-22 |
WO1999011256A8 (fr) | 1999-08-05 |
CN1200366A (zh) | 1998-12-02 |
DE69832722T2 (de) | 2006-09-07 |
US6313170B1 (en) | 2001-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ashmead | The absorption and metabolism of iron amino acid chelate | |
US4315927A (en) | Dietary supplementation with essential metal picolinates | |
EP0524633B1 (en) | Pharmaceutical composition suitable for influencing the reticuloendothelial system | |
US6818228B1 (en) | Dietary supplements containing ultradense calcium citrate and carbonyl iron | |
HUE028029T2 (en) | A method of treating chronic kidney disease | |
CA2624619C (en) | Improved toleration iron supplement compositions | |
KR100363031B1 (ko) | 신조직형성과자가면역질환의치료또는예방을위한마그네슘-계생성물의용도 | |
Harrison et al. | Vitamin D and citrate metabolism: Studies on rachitic infants | |
EP1318804B1 (en) | Iron compositions | |
WO1999011256A1 (fr) | L-threonate ferreux, composition pharmaceutique le contenant et son utilisation pour reduire et traiter l'anemie chez l'homme | |
JP2011510922A (ja) | 骨粗鬆症の予防及び回復のためのカルシウム、マグネシウム、亜鉛、ビタミンd3を含む調剤 | |
US20070218126A1 (en) | Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis | |
CN107417556A (zh) | L‑天门冬氨酸螯合钙及其制备方法 | |
WO1995018625A1 (fr) | Composition renfermant des extraits de tortues et notamment de tortues hargneuses, sa preparation et son utilisation | |
Levey et al. | A study to determine the toxicity of fumaric acid | |
WO2007009393A1 (fr) | Utilisation d'acide chlorogene dans la fabrication de medicaments pour l'accroissement de l'effet de cellules de moelle osseuse | |
CN111450255B (zh) | 一种缓解睡眠-呼吸暂停综合征的药物组合物及其制备方法 | |
CN109453147B (zh) | 脂溶性维生素组合物及其应用 | |
Spencer et al. | Effect of lysine on calcium metabolism in man | |
CN109223766A (zh) | 改善人体微循环提高人体免疫力的组合物和制备工艺 | |
THERAP | section of Eberapeuticz anb Pbarmacoloop. | |
Youmans | Mineral deficiencies | |
CN101584687A (zh) | α-酮戊二酸铁在制备补铁药物及保健品中的应用 | |
CN109394776B (zh) | 一种治疗弥漫性肺间质纤维化的中药组分方及其应用 | |
CN107595829B (zh) | 一种防治肾性骨营养不良的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WR | Later publication of a revised version of an international search report | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020007002104 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09486569 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998940049 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998940049 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007002104 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998940049 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007002104 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007002104 Country of ref document: KR |